Compare HFFG & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HFFG | ANIX |
|---|---|---|
| Founded | 1997 | 1982 |
| Country | United States | United States |
| Employees | 960 | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.8M | 88.8M |
| IPO Year | 2016 | 2013 |
| Metric | HFFG | ANIX |
|---|---|---|
| Price | $1.74 | $2.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $8.67 |
| AVG Volume (30 Days) | 125.7K | ★ 174.0K |
| Earning Date | 05-11-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.65 | 12.82 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $1,228,282,000.00 | $210,000.00 |
| Revenue This Year | $5.59 | N/A |
| Revenue Next Year | $2.24 | N/A |
| P/E Ratio | $90.00 | ★ N/A |
| Revenue Growth | ★ 2.21 | N/A |
| 52 Week Low | $1.38 | $2.32 |
| 52 Week High | $3.86 | $5.46 |
| Indicator | HFFG | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 35.11 | 52.11 |
| Support Level | $1.38 | $2.38 |
| Resistance Level | $2.30 | $3.12 |
| Average True Range (ATR) | 0.11 | 0.21 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 14.67 | 62.31 |
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, frozen and dry food, and non-food products to Asian restaurants and other foodservice customers throughout the United States. The company's business consists of one operating segment: HF Group, which operates solely in the United States. The company's product list consists of Meat, Poultry & Seafood, Sauces & Oils, Takeout Items (Boxes, Chopsticks & Utensils), Raw Ingredients (Flour, Cornstarch, Spices), Cleaning Supplies, and Rice & Grains.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.